TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05283161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol and tetrahydrocannabinol
Description: CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol and tetrahydrocannabinol
Description: CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol and tetrahydrocannabinol
Description: CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
Study: NCT05095844

Intervention type: BIOLOGICAL
Intervention: vaccinated
Description: Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
Study: NCT05825456

Intervention type: PROCEDURE
Intervention: endoprosthetic reconstruction
Description: This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.

Intervention type: PROCEDURE
Intervention: Intramedullary nailing
Description: This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
Study: NCT06262841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional burs
Description: Conventional burs used as an osteotomy device
Study: NCT05825456

Intervention type: PROCEDURE
Intervention: Open reduction internal fixation with plate and screws
Description: This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
Study: NCT04836299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to receive a single of placebo.
Study: NCT05077943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and chest mobilization exercises
Description: Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
Study: NCT06022627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama Yoga
Description: Doing practice of paranayam yoga which including breathing exercises yoga-life energy
Study: NCT05671302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk Together
Description: Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
Study: NCT05440227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2 Lyo. Injection 500mg
Description: PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 0.9% normal saline
Description: 0.9% normal saline 500ml will be administered weekly for 8 weeks.
Study: NCT05666466

Intervention type: DIAGNOSTIC_TEST
Intervention: extratympanic electrocochleograhy
Description: electrophysiological test

Intervention type: DIAGNOSTIC_TEST
Intervention: extratympanic electrocochleograhy
Description: electrophysiological test
Study: NCT05024695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIject™ Implant
Description: The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
Study: NCT05278130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional vaginal swabs
Description: Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
Study: NCT05077943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Second phase cardiac rehabilitation
Description: Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
Study: NCT05387187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pu Yang Wan Wu Tang plus Pentoxifylline
Description: Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 100mg TID
Study: NCT03458611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Intervention
Description: The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Intervention
Description: The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
Study: NCT06552039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyherbal Hair Oil
Description: Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum
Description: First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical
Study: NCT05263700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPi-46
Description: FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
Study: NCT06552039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Hair Serum
Description: Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
Study: NCT05760248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection, 6.0%
Description: The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
Study: NCT05565118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Treatment
Description: During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Electrocorticography
Description: Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
Study: NCT06398912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Based Intervention
Description: Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
Study: NCT06572631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05760248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution for Injection (no active ingredient)
Description: Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
Study: NCT06166524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation for atrial fibrillation using pulsed-field energy
Description: Patients will undergo pulmonary vein isolation using pulsed-field energy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conservative arm
Description: Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
Study: NCT04825912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience
Description: The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
Study: NCT05806892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thera Pearl
Description: You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath.
Study: NCT05487417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
Study: NCT05407155

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bevacizumab plus nab-paclitaxel and platinum
Description: Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
Study: NCT04864028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
Study: NCT06572631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06436183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camoteskimab
Description: Drug Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camoteskimab
Description: Drug Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study: NCT05892094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance and Aerobic Training
Description: For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
Study: NCT06376058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine 1% Injectable Solution
Description: • in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: • in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
Study: NCT04875351

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
Description: The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
Study: NCT06583213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Spinal Anaesthesia.
Description: An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional Spinal Anaesthesia.
Description: An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Spinal Anaesthesia
Description: Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Spinal Anaesthesia
Description: Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes.
Study: NCT05985330

Intervention type: OTHER
Intervention: Measurement of FeNO
Description: Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
Study: NCT06029452

Intervention type: OTHER
Intervention: Machine learning algorithm
Description: Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
Study: NCT06046898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation with or without resistance
Description: non-invasive ventilation with or without resistance.
Study: NCT05472246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a virtual reality headset
Description: VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
Study: NCT05635487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib